# Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers

> **NCT00110591** · PHASE1 · COMPLETED · sponsor: **CytoDyn, Inc.** · enrollment: 20 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** PRO 140

## Key facts

- **NCT ID:** NCT00110591
- **Lead sponsor:** CytoDyn, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04-16
- **Primary completion:** 2005-11-07
- **Final completion:** 2008-03-31
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00110591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00110591, "Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00110591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*